Fine needle aspiration and core biopsy of a right posterior iliac lesion in [**2101-5-27**] revealed metastatic renal cell carcinoma.
The torso CT showed bilateral subcentimeter pulmonary nodules and mediastinal and hilar adenopathy.
Follow-up scans revealed improvement in the lung and bone lesions.
He began cycle 2,  week 1 high-dose IL-2 therapy on [**2102-3-16**], receiving 12 of 14 doses complicated by toxic encephalopathy.
Vital Signs: 95.7, 82, 20, 140/72, O2 saturation 96% on room air.
LABORATORY DATA:  Admission labs: WBC 9, hemoglobin 11.3, hematocrit 33.8, platelet count 398,000.
INR 1.1.
BUN 24, creatinine 1.6, sodium 138, potassium 4.6, chloride 106, CO2 21, glucose 83.
ALT 33, AST 24, LDH 174, CK 16, alkaline phosphatase 137, total bilirubin 1.2.
His admission weight was 83 kg and he received interleukin-2 600,000 international units per kilo equaling 49.9 million units I.V.
After his first dose of IL-2, he required a fluid boluses to improve his blood pressure which were successful.
His blood pressure stabilized in the ICU and he was weaned off Neo-Synephrine and was weaned down on dopamine prior to returning to our floor the following morning.
Other side effects during this week included nausea improved with antiemetic therapy; mucositis improved with oral agents, and development of an erythematous pruritic skin rash.
During this week he developed acute renal failure with a peak creatinine of 4.1 with associated oliguria.
Metabolic acidosis was noted with a minimum bicarbonate of 19 improved with bicarbonate replacement intravenously.
Serum bicarbonate, creatinine and urine output were monitored closely.
Electrolytes were monitored and repleted per protocol.
He developed mild hyperbilirubinemia with a peak bilirubin of 2.0 improved to 1.1 at the time of discharge.
FOLLOW-UP PLANS:  Mr. [**Known lastname 82888**] will return to clinic in 4 weeks after CT scans to assess disease response.
